ABSTRACT
This chapter makes a projections based on the number of projects at different phases as of 2012. It suggests what they could end up yielding in terms of numbers of new products eventually reaching the market. Let's consider firstly projects at Phase III. On average a project at this phase will reach the market in about three years. In 2009 there were 544 projects at Phase III, according to Pharmaprojects Citeline. On average a project at Phase II will take about six years to reach the market. In 2006 there were 1,309 projects at that phase, whereas by 2012 that figure had reached 1,882. This is a 44 per cent increase in the number of Phase II projects. For projections from Phase I, It assumes that on average it takes eight years for projects to progress from this phase to the market. Finally, let's look at the projection for the preclinical phase.
